Viravaxx AG
Develops hepatitis B vaccines; lead candidate in Phase II clinical trials elicits preS-specific IgG responses in vaccine‑naïve adults and chronically infected patients.
Employees
loading...
Funding Status
loading...
Established
loading...
Total Funding
loading...
ARR
loading...
Insights
Loading Insights...
Loading Insight content to display...
Loading Insights...
Loading Insight content to display...
Founders
loading...
Notable Customers
loading...
Funding
Workforce
Functional Distribution
N/A
Open Positions
N/A
Diversity
N/A
